AR111241A1 - Compuestos de imidazo-piperidina fusionada como inhibidores de jak - Google Patents
Compuestos de imidazo-piperidina fusionada como inhibidores de jakInfo
- Publication number
- AR111241A1 AR111241A1 ARP180100542A ARP180100542A AR111241A1 AR 111241 A1 AR111241 A1 AR 111241A1 AR P180100542 A ARP180100542 A AR P180100542A AR P180100542 A ARP180100542 A AR P180100542A AR 111241 A1 AR111241 A1 AR 111241A1
- Authority
- AR
- Argentina
- Prior art keywords
- 3alkyl
- nitrogen atom
- optionally substituted
- membered heterocyclyl
- taken together
- Prior art date
Links
- AIAJYBLPGVBVSS-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-imidazo[4,5-b]pyridine Chemical class C1CCNC2=C1NC=N2 AIAJYBLPGVBVSS-UHFFFAOYSA-N 0.000 title 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 17
- 229910052757 nitrogen Inorganic materials 0.000 abstract 14
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 13
- 125000000623 heterocyclic group Chemical group 0.000 abstract 12
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NFGODEMQGQNUKK-UHFFFAOYSA-M [6-(diethylamino)-9-(2-octadecoxycarbonylphenyl)xanthen-3-ylidene]-diethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C21 NFGODEMQGQNUKK-UHFFFAOYSA-M 0.000 abstract 1
- KCNKJCHARANTIP-SNAWJCMRSA-N allyl-{4-[3-(4-bromo-phenyl)-benzofuran-6-yloxy]-but-2-enyl}-methyl-amine Chemical compound C=1OC2=CC(OC/C=C/CN(CC=C)C)=CC=C2C=1C1=CC=C(Br)C=C1 KCNKJCHARANTIP-SNAWJCMRSA-N 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Chemical group 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Abstract
Los compuestos o una sal farmacéuticamente aceptable del mismo, son útiles como inhibidores de la quinasa JAK. También se proveen composiciones farmacéuticas que comprenden tales compuestos, métodos para usar tales compuestos para trata procesos y enfermedades respiratorias, e intermediarios útiles para preparar tales compuestos. Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1), donde: R¹ se selecciona entre hidrógeno, C₁₋₃alquilo, y C₃₋₆cicloalquilo, y X se selecciona entre -C(O)R² y -CH₂R¹⁶, o R¹ se selecciona entre -(CH₂)₂NR²⁰R²¹ y un heterociclilo de 4 - 6 miembros que contiene un átomo de nitrógeno, donde el átomo de nitrógeno está sustituido opcionalmente con R²², y X se selecciona entre -CH₂OR²³ y -C(O)OR²⁴; donde R² se selecciona entre -NR¹³R¹⁴ y -OR¹⁵; R¹³ y R¹⁴ tomados junto con el átomo de nitrógeno al cual están unidos forman un heterociclilo monocíclico o bicíclico de 6 ó 7 miembros que contiene un átomo adicional de nitrógeno, donde el átomo de nitrógeno adicional está sustituido con R³ y el heterociclilo está sustituido opcionalmente con uno o dos R⁴, o R¹³ y R¹⁴ tomados junto con el átomo de nitrógeno al cual están unidos forman un heterociclilo de entre 5- y 6-miembros, donde el heterociclilo está sustituido opcionalmente con -NR⁵R⁶ y R⁷, o R¹³ y R¹⁴ tomados junto con el átomo de nitrógeno al cual están unidos forman morfolinilo, o R¹³ es R⁸ y R¹⁴ es R⁹; R³ se selecciona entre hidrógeno, C₃₋₆cicloalquilo, y C₁₋₃alquilo, donde C₁₋₃alquilo está sustituido opcionalmente con -OH o -OC₁₋₃alquilo; R⁴ es C₁₋₃alquilo, donde C₁₋₃alquilo está sustituido opcionalmente con -OH; R⁵ y R⁶ son independientemente C₁₋₃alquilo o R⁵ y R⁶ tomados junto con el átomo de nitrógeno al cual están unidos forman un heterociclilo de 5 ó 6 miembros que incluye opcionalmente un átomo de oxígeno; R⁷ es C₁₋₃alquilo, opcionalmente sustituido con a heterociclilo de 5 ó 6 miembros que contiene un átomo de nitrógeno; R⁸ es hidrógeno o C₁₋₃alquilo; R⁹ es -(CH₂)₂NR¹⁰R¹¹ o un heterociclilo de 4 - 6 miembros que contiene un átomo de nitrógeno donde el átomo de nitrógeno está sustituido con R¹²; R¹⁰ y R¹¹ son independientemente C₁₋₃alquilo o R¹⁰ y R¹¹ tomados junto con el átomo de nitrógeno al cual están unidos forman un heterociclilo de 5 ó 6 miembros; R¹² es C₁₋₃alquilo o C₃₋₆cicloalquilo, donde C₁₋₃alquilo está sustituido opcionalmente con -OH; R¹⁵ se selecciona entre C₁₋₃alquilo, C₃₋₆cicloalquilo, y un heterociclilo de 5 ó 6 miembros incluyendo un heteroátomo que se selecciona entre nitrógeno y oxígeno, donde C₁₋₃alquilo está sustituido opcionalmente con -OH o N(C₁₋₃alquil)₂, y un heterociclilo de 5 ó 6 miembros está sustituido opcionalmente con C₁₋₃alquilo; R¹⁶ se selecciona entre -NR¹⁷R¹⁸ y -OR¹⁹; R¹⁷ y R¹⁸ son independientemente C₁₋₄alquilo o C₃₋₅cicloalquilo o R¹⁷ y R¹⁸ tomados junto con el átomo de nitrógeno al cual están unidos forman un heterociclilo de 5 ó 6 miembros que incluye opcionalmente un átomo de oxígeno, donde el heterociclilo está sustituido opcionalmente con C₁₋₃alquilo; R¹⁹, R²⁰, R²¹, R²², R²³, y R²⁴ se seleccionan independientemente entre hidrógeno y C₁₋₃alquilo; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762469073P | 2017-03-09 | 2017-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111241A1 true AR111241A1 (es) | 2019-06-19 |
Family
ID=61683956
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100543A AR111242A1 (es) | 2017-03-09 | 2018-03-08 | Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak |
| ARP180100542A AR111241A1 (es) | 2017-03-09 | 2018-03-08 | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100543A AR111242A1 (es) | 2017-03-09 | 2018-03-08 | Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak |
Country Status (20)
| Country | Link |
|---|---|
| US (10) | US10196393B2 (es) |
| EP (2) | EP3592742B1 (es) |
| JP (2) | JP6974487B2 (es) |
| KR (2) | KR102533646B1 (es) |
| CN (2) | CN110382498B (es) |
| AR (2) | AR111242A1 (es) |
| AU (2) | AU2018231035B2 (es) |
| BR (2) | BR112019018649A2 (es) |
| CA (1) | CA2997772A1 (es) |
| DK (1) | DK3592742T3 (es) |
| EA (2) | EA037748B1 (es) |
| ES (1) | ES2882186T3 (es) |
| IL (2) | IL268689B2 (es) |
| MX (2) | MX388750B (es) |
| PH (2) | PH12019501941A1 (es) |
| PT (1) | PT3592742T (es) |
| SG (2) | SG11201907840RA (es) |
| TW (2) | TWI754019B (es) |
| WO (2) | WO2018165392A1 (es) |
| ZA (2) | ZA201905585B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA123633C2 (uk) | 2015-11-03 | 2021-05-05 | Тереванс Байофарма Ар Енд Ді Айпі, Елелсі | Сполуки інгібітору jak-кінази для лікування респіраторного захворювання |
| US10556901B2 (en) * | 2015-11-03 | 2020-02-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors |
| TWI754019B (zh) * | 2017-03-09 | 2022-02-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 含有4員雜環醯胺之jak抑制劑 |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| CA3059785A1 (en) | 2017-05-01 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a jak inhibitor compound |
| WO2020051135A1 (en) | 2018-09-04 | 2020-03-12 | Theravance Biopharma R&D Ip, Llc | Process for preparing jak inhibitors and intermediates thereof |
| BR112021004052A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | amidas de dimetil-amino azetidina como inibidores de jak |
| JP7383696B2 (ja) | 2018-09-04 | 2023-11-20 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋ阻害剤としての５員～７員の複素環アミド |
| CA3113667A1 (en) | 2018-10-29 | 2020-05-07 | Theravance Biopharma R&D Ip, Llc | 2-azabicyclo hexane compound as jak inhibitor |
| EP3932919B1 (en) | 2019-02-25 | 2024-06-26 | Henan Medinno Pharmaceutical Technology Co., Ltd. | Jak inhibitor compound and use thereof |
| PH12021552130A1 (en) | 2019-03-05 | 2022-08-31 | Incyte Corp | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
| CN114901659A (zh) * | 2019-11-26 | 2022-08-12 | 施万生物制药研发Ip有限责任公司 | 作为jak抑制剂的稠合嘧啶吡啶酮化合物 |
| CN113121509B (zh) * | 2019-12-30 | 2024-04-26 | 河南迈英诺医药科技有限公司 | Jak抑制剂化合物及其用途 |
| TW202144343A (zh) * | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| EP3944859A1 (en) * | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| WO2022178215A1 (en) * | 2021-02-19 | 2022-08-25 | Theravance Biopharma R&D Ip, Llc | Amino amide tetrahydro imidazo pyridines as jak inhibitors |
| CA3223194A1 (en) * | 2021-06-25 | 2022-12-29 | Theravance Biopharma R&D Ip, Llc | Imidazolo indazole compounds as jak inhibitors |
| EP4450492A4 (en) * | 2021-12-17 | 2025-10-15 | Daewoong Pharmaceutical Co Ltd | NEW ACID ADDITION SALT AND CRYSTALLINE FORM OF (2R,3S)-2-(3-(4,5-DICHLORO-1H-BENZO[D]IMIDAZOL-1-YL)PROPYL)PIPERIDIN-3-OL |
| CN117658852A (zh) * | 2023-11-15 | 2024-03-08 | 西北工业大学 | 取代苯氧乙酰肼类化合物及其制备方法和作为stat3的抗炎抑制剂的应用 |
| WO2025157904A1 (en) * | 2024-01-24 | 2025-07-31 | Kiox Pharmaceuticals Aps | Inhalable formulations of ruxolitinib, methods of manufacture and uses thereof |
| CN118903009B (zh) * | 2024-10-11 | 2025-01-21 | 江苏长泰药业股份有限公司 | 一种调节呼吸道微生态的丙酮酸钠气雾剂及其制备方法和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| EP1648455A4 (en) | 2003-07-23 | 2009-03-04 | Exelixis Inc | MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| WO2010114971A1 (en) | 2009-04-03 | 2010-10-07 | Sepracor Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| HUE035612T2 (en) | 2009-12-21 | 2018-05-28 | Samumed Llc | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| EP2338888A1 (en) * | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| US8575336B2 (en) * | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| WO2013060636A1 (en) | 2011-10-25 | 2013-05-02 | Sanofi | 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP3318565B1 (en) | 2013-12-05 | 2021-04-14 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
| CR20160525A (es) | 2014-05-14 | 2016-12-20 | Pfizer | Pirazolopiridinas y pirazolopirimidinas |
| WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
| KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
| US10556901B2 (en) | 2015-11-03 | 2020-02-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors |
| ES2864035T3 (es) | 2015-11-03 | 2021-10-13 | Topivert Pharma Ltd | Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus |
| UA123633C2 (uk) | 2015-11-03 | 2021-05-05 | Тереванс Байофарма Ар Енд Ді Айпі, Елелсі | Сполуки інгібітору jak-кінази для лікування респіраторного захворювання |
| TWI754019B (zh) * | 2017-03-09 | 2022-02-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 含有4員雜環醯胺之jak抑制劑 |
| SG11201909376TA (en) | 2017-05-01 | 2019-11-28 | Theravance Biopharma R&D Ip Llc | Crystalline forms of a jak inhibitor compound |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| CA3059785A1 (en) | 2017-05-01 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a jak inhibitor compound |
| KR102032418B1 (ko) | 2017-06-15 | 2019-10-16 | 한국화학연구원 | 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| JP7383696B2 (ja) | 2018-09-04 | 2023-11-20 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋ阻害剤としての５員～７員の複素環アミド |
| BR112021004052A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | amidas de dimetil-amino azetidina como inibidores de jak |
| WO2020051135A1 (en) | 2018-09-04 | 2020-03-12 | Theravance Biopharma R&D Ip, Llc | Process for preparing jak inhibitors and intermediates thereof |
-
2018
- 2018-03-08 TW TW107107939A patent/TWI754019B/zh not_active IP Right Cessation
- 2018-03-08 DK DK18711796.5T patent/DK3592742T3/da active
- 2018-03-08 MX MX2019010541A patent/MX388750B/es unknown
- 2018-03-08 KR KR1020197029543A patent/KR102533646B1/ko active Active
- 2018-03-08 SG SG11201907840RA patent/SG11201907840RA/en unknown
- 2018-03-08 BR BR112019018649A patent/BR112019018649A2/pt not_active IP Right Cessation
- 2018-03-08 MX MX2019010539A patent/MX388749B/es unknown
- 2018-03-08 AR ARP180100543A patent/AR111242A1/es unknown
- 2018-03-08 CA CA2997772A patent/CA2997772A1/en active Pending
- 2018-03-08 EA EA201992128A patent/EA037748B1/ru unknown
- 2018-03-08 AR ARP180100542A patent/AR111241A1/es not_active Application Discontinuation
- 2018-03-08 EA EA201992126A patent/EA037261B1/ru not_active IP Right Cessation
- 2018-03-08 EP EP18711796.5A patent/EP3592742B1/en active Active
- 2018-03-08 EP EP18712398.9A patent/EP3592743A1/en not_active Withdrawn
- 2018-03-08 CN CN201880016693.XA patent/CN110382498B/zh not_active Expired - Fee Related
- 2018-03-08 JP JP2019548449A patent/JP6974487B2/ja active Active
- 2018-03-08 PT PT187117965T patent/PT3592742T/pt unknown
- 2018-03-08 US US15/915,418 patent/US10196393B2/en active Active
- 2018-03-08 KR KR1020197029560A patent/KR102526764B1/ko active Active
- 2018-03-08 SG SG11201907544VA patent/SG11201907544VA/en unknown
- 2018-03-08 JP JP2019548369A patent/JP7134990B2/ja active Active
- 2018-03-08 AU AU2018231035A patent/AU2018231035B2/en not_active Ceased
- 2018-03-08 WO PCT/US2018/021489 patent/WO2018165392A1/en not_active Ceased
- 2018-03-08 WO PCT/US2018/021492 patent/WO2018165395A1/en not_active Ceased
- 2018-03-08 BR BR112019018648-4A patent/BR112019018648A2/pt not_active IP Right Cessation
- 2018-03-08 ES ES18711796T patent/ES2882186T3/es active Active
- 2018-03-08 AU AU2018231032A patent/AU2018231032B2/en not_active Ceased
- 2018-03-08 US US15/915,434 patent/US10208040B2/en active Active
- 2018-03-08 CN CN201880017046.0A patent/CN110461839B/zh active Active
- 2018-03-08 TW TW107107936A patent/TWI779016B/zh not_active IP Right Cessation
- 2018-12-17 US US16/222,647 patent/US10392386B2/en active Active
- 2018-12-19 US US16/225,473 patent/US10519153B2/en active Active
-
2019
- 2019-07-15 US US16/511,410 patent/US10550118B2/en active Active
- 2019-08-13 IL IL268689A patent/IL268689B2/en unknown
- 2019-08-13 IL IL268679A patent/IL268679B/en unknown
- 2019-08-22 PH PH12019501941A patent/PH12019501941A1/en unknown
- 2019-08-23 ZA ZA2019/05585A patent/ZA201905585B/en unknown
- 2019-08-26 ZA ZA2019/05618A patent/ZA201905618B/en unknown
- 2019-08-29 PH PH12019501985A patent/PH12019501985A1/en unknown
- 2019-11-11 US US16/679,676 patent/US11254669B2/en active Active
- 2019-12-03 US US16/701,426 patent/US10954237B2/en active Active
-
2021
- 2021-02-12 US US17/248,907 patent/US11453668B2/en active Active
-
2022
- 2022-01-14 US US17/576,089 patent/US11667637B2/en active Active
- 2022-08-10 US US17/885,475 patent/US11878977B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111241A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak | |
| AR098721A1 (es) | Inhibidores de biarilo de tirosina quinasa de bruton | |
| AR111776A1 (es) | Heteroarilos inhibidores de las proteínas ras mutantes de g12c | |
| AR096643A1 (es) | Procedimiento de síntesis para la preparación de análogos macrocíclicos c1-ceto de halicondrina b e intermediarios útiles en la misma incluyendo intermediarios que contienen grupos -so₂-(p-tolilo) | |
| AR113888A1 (es) | Derivados de indol macrocíclicos sustituidos | |
| AR098492A1 (es) | Derivados de purina | |
| EA202190196A1 (ru) | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 | |
| AR109905A1 (es) | Pirrolidinas sustituidas como moduladores de cftr | |
| AR087901A1 (es) | Derivados dihidroquinolina-2-ona como inhibidores de la aldosterona sintasa y procedimiento para su obtencion | |
| AR110089A1 (es) | Inhibidores de magl | |
| AR089807A1 (es) | Compuestos de imidazopirrolidinona | |
| CU24448B1 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
| AR092742A1 (es) | Piridinonas antifibroticas | |
| AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| AR099890A1 (es) | Inhibidores de histona demetilasas | |
| AR110988A1 (es) | Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados | |
| AR113886A1 (es) | Derivados de indol macrocíclicos | |
| AR091261A1 (es) | Derivados de alcoholes 1-fenil-2-piridinilalquilicos como inhibidores de la fosfodiesterasa | |
| AR099789A1 (es) | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina | |
| AR090678A1 (es) | Derivados de fenil-tetrahidroisoquinolina como inhibidores de la aldosterona-sintasa y un metodo para su sintesis | |
| AR098909A1 (es) | Compuesto heterocíclico | |
| AR113887A1 (es) | Derivados de indol macrocíclicos sustituidos con cloro | |
| PE20211769A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
| AR121913A1 (es) | Compuestos terapéuticos | |
| AR113933A1 (es) | Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |